# Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years

> **NCT05976100** · PHASE1 · COMPLETED · sponsor: **Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"** · enrollment: 90 (actual)

## Conditions studied

- Smallpox
- Monkeypox
- Cowpox
- Vaccinia Virus Infection

## Interventions

- **DRUG:** NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally
- **DRUG:** NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)
- **DRUG:** NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)
- **DRUG:** NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days
- **DRUG:** NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 a day orally for 6 days. (Total 600 mg NIOCH-14 per day for 6 days)
- **DRUG:** NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 twice a day orally for 6 days. (Total 1200 mg NIOCH-14 per day for 6 days)

## Key facts

- **NCT ID:** NCT05976100
- **Lead sponsor:** Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-04
- **Primary completion:** 2021-02-27
- **Final completion:** 2022-03-09
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05976100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05976100, "Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05976100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*